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Abstract
Background: The mammalian Vps10p sorting receptor family is a group of 5 type I membrane
homologs (Sortilin, SorLA, and SorCS1-3). These receptors bind various cargo proteins via their
luminal Vps10p domains and have been shown to mediate a variety of intracellular sorting and
trafficking functions. These proteins are highly expressed in the brain. SorLA has been shown to be
down regulated in Alzheimer's disease brains, interact with ApoE, and modulate Aβ production.
Sortilin has been shown to be part of proNGF mediated death signaling that results from a complex
of Sortilin, p75NTR and proNGF. We have investigated and provide evidence for γ-secretase
cleavage of this family of proteins.
Results: We provide evidence that these receptors are substrates for presenilin dependent γ-
secretase cleavage. γ-Secretase cleavage of these sorting receptors is inhibited by γ-secretase
inhibitors and does not occur in PS1/PS2 knockout cells. Like most γ-secretase substrates, we find
that ectodomain shedding precedes γ-secretase cleavage. The ectodomain cleavage is inhibited by
a metalloprotease inhibitor and activated by PMA suggesting that it is mediated by an α-secretase
like cleavage.
Conclusion: These data indicate that the α- and γ-secretase cleavages of the mammalian Vps10p
sorting receptors occur in a fashion analogous to other known γ-secretase substrates, and could
possibly regulate the biological functions of these proteins.
Background
γ-Secretase is a multi-component protease complex com-
prised of Presenilin (PS) 1 or 2 with Aph-1, Pen-2, and
Nicastrin [1,2] that cleaves type I membrane proteins
within their transmembrane domains. γ-Secretase cata-
lyzes a number of important physiological and patho-
physiological cleavages. Following ectodomain cleavage
of the amyloid precursor protein (APP) [3] by β-secretase,
γ-secretase cleavage releases the amyloid beta peptide (Aβ)
that accumulates in the brains of patients with Alzhe-
imer's disease (AD) [4]. γ-Secretase also plays a key role in
mediating signaling via the Notch receptors [5-7]. In most
cases, knockout of presenilin or other components of the
γ-secretase complex produces an embryonic lethal pheno-
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type, that resembles the phenotype produced by knockout
of Notch 1.
To date, more than 25 γ-secretase substrates have been
identified. [8-28]. All identified γ-secretase substrates are
type I transmembrane proteins [29] and contain a puta-
tive stop transfer sequence immediately following the
transmembrane region [30]. In most cases, ectodomain
shedding precedes intramembrane γ-secretase cleavage
[31]. For a growing lists of substrates, γ-secretase cleavage
has been shown to mediate downstream signaling events
[32].
Although many proteases preferentially cleave at consen-
sus sequences within the substrate, no consensus
sequence for cleavage by γ-secretase has been identified. γ-
Secretase cleavage always occurs within a putative hydro-
phobic transmembrane region, but a variety of different
sites are cleaved even in a single substrate. Alignment of γ-
secretase substrate transmembrane domains provides lit-
tle insight into the sequence requirements for proteolysis
to occur (Figure 1a) [33]. Likewise mutations of cleavage
sites have provided little definitive information on the
nature of the cleavage, though several models have been
proposed [34].
Following ectodomain shedding, γ-secretase cleavage lib-
erates both the cytoplasmic fragment and a small secreted
peptide. For several substrates the liberated cytoplasmic
domain has been shown to translocate to the nucleus
where it is involved in nuclear signaling (Notch ErbB4,
Delta-1 Jagged, APLP1/2). This process is more generally
referred to as regulated intramembrane proteolysis (RIP).
RIP of Notch has been intensively studied. Ligand binding
to the Notch extracellular domain results in ectodomain
cleavage, which is then followed by γ-secretase cleavage.
Once liberated the notch intracellular domain (NICD)
translocates to the nucleus where it binds to CSL family of
transcription factors [35,36]. Notch binding to CSL has
been shown to convert CSL from a transcriptional repres-
sor to a transcriptional activator [5]. Analogously nuclear
signaling of the CD44 [37,38] and N-cadherin [39] cyto-
plasmic domains following γ-secretase cleavage is indi-
rectly achieved through CBP (CREB-binding protein)
activation or suppression, respectively. In some cases
nuclear translocation of the cytoplasmic domain is not
required for signaling following γ-secretase cleavage
[8,13,14,40]. Not all γ-secretase substrates appear to
undergo RIP, as ligand binding is not necessary for the ini-
tiation of cleavage. For example, APP does not appear to
require ligand association in order to initiate ectodomain
shedding which occurs prior to γ-secretase cleavage.
In most cases, signaling initiated by γ-secretase cleavage
appears to be an activation event. However, cleavage of
the substrate deleted in colorectal cancer (DCC) attenu-
ates receptor-mediated intracellular signaling pathways
that are critical in regulating glutamatergic synaptic trans-
mission and memory processes [18,41].
Because of their topologic similarity to other γ-secretase
substrates and evidence for ectodomain shedding [42]
(Figure 1a), we hypothesized that the mammalian Vps10p
containing family of proteins might be γ-secretase sub-
strates. Sortilin, SorLA and SorCS1, 2, and 3 comprise the
five identified mammalian Vps10p sorting receptors and
have a number of features in common. First, all are type I
membrane proteins (Figure 1b). Second, all contain a
luminal/extracellular cysteine-rich Vps10p domain
homologous to the binding domain of the yeast sorting
receptor for carboxypeptidase Y. Third, all contain a puta-
tive furin cleavage site. SorCS1-3 and SorLA also contain
additional extracellular domains thought to be involved
in ligand binding (Figure 1b). Sortilin is also known as
neurotensin receptor 3 or gp95, and SorLA is often called
LR11. These receptors are hypothesized to have pleio-
tropic functions in chaperoning and targeting various car-
goes bound to their luminal Vps10p domains between
various intracellular organelles [43,44].
These sorting receptors are expressed at high levels in the
CNS and in neurons [44-46]. Sortilin is part of the
machinery that governs cell survival in developing neuro-
nal tissue and a key determinant in the induction of post-
traumatic neuronal apoptosis [47]. It also mediates rapid
endocytosis of lipoprotein lipase [48], neurotensin [49],
and the proform of nerve growth factor [47]. Sortilin has
been shown to target proteins in the Golgi for transport to
late endosomes. Of its many sorting and signaling func-
tions, Sortilin was shown to play a role in p75NTR "death
signaling". The cell death signal is a result of a complex of
p75NTR, Sortilin and the precursor form of nerve growth
factor (proNGF) [47] or pro brain-derived neurotrophic
factor [50].
Recent data have suggested a role for SorLA in AD. SorLA
was shown to be a receptor for, and interact with, ApoE
[51-54]. In addition, it is reduced in AD brains versus age
matched controls, interacts with APP [55] and regulates
Aβ production [56,57].
we provide evidence that Sortilin, SorCS1b and SorLA are
sequentially cleaved by an α-secretase like activity fol-
lowed by γ-secretase. α-Secretase cleavage results in secre-
tion of a large extracellular domain of the Vps10p
substrates and γ-secretase liberates a COOH-terminal frag-
ment (CTF) from the membrane. These data extend very
recent studies demonstrating that Sortilin, SorCS1,
SorCS2, SorCS3, and SorLA undergo ectodomain shed-Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
Page 3 of 11
(page number not for citation purposes)
ding [42] and that SorLA can undergo γ-secretase cleavage
[28].
Results
Evidence for sequential α- and γ-secretase cleavage of 
Sortilin
HEK 293T cells were transiently transfected with Sortilin
containing a V5 epitope tag at the COOH-terminus
(SorV5) and treated with a variety of inhibitors or PMA.
The epitope tagged SorV5 construct was used because we
have been unable to obtain a reliable anti-sortilin COOH-
terminal antibody. Cell lysates and media from the tran-
siently transfected cells were analyzed by SDS PAGE and
Western blotting. Consistent with previous studies show-
ing that the untagged Sortilin holoprotein is a ~95 kDa
glycoprotein [58], transfection of the SorV5 resulted in
Schematics of γ-secretase substrates and the mammalian Vps10p proteins Figure 1
Schematics of γ-secretase substrates and the mammalian Vps10p proteins. a) Alignment of the transmembrane 
domains and juxtamembrane region of known γ-secretase substrates The number of additional amino acids in the cytoplasmic 
domain following the sequence shown is indicated by "+ aa". b) A schematic of the human Vps10p containing proteins is 
shown. Sortilin is a 95 kDa glycoprotein. SorCS1, 2, and 3 contain a leucine rich domain and are ~130 kDa. The largest of the 
homologs, SorLA is 250 kDa and contains a host of receptor binding domains including 14 different low density lipoprotein 
receptor sites, and EGF repeat, and a fribronectin type III repeat.
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expression of a 95 kDa protein that was detected both by
an anti-Sortilin NH2-terminal antibody (not shown) and
anti-V5 (Figure 2a). In addition, a SorV5 CTF was detected
with the anti-V5 antibody at ~16 kDa (Figure 2a). This
band was not detected by the NH2-terminal Sortilin anti-
body (not shown). γ-Secretase inhibitor treatment mark-
edly increased the ~16 kDa SorV5 CTF in cell lysates of
cells transiently overexpressing SorV5 (Figure 2a), but did
not appreciably alter the amount of soluble Sortilin (sSor)
that was detected in the media with an anti-Sortilin NH2-
terminal antibody but not anti-V5 (Figure 2a). Activation
of protein kinase C by PMA has been shown to enhance
ectodomain shedding of APP by α-secretase [59-62] and
resulted in an increase in sSor detected in the media (Fig-
ure 2a). GM6001, a broad spectrum hydroxamic acid
based inhibitor of matrixmetalloproteases and disin-
tegrin-metalloproteases [63], has been shown to inhibit
α-secretase cleavage of APP and decreased sSor levels
detected in the media. Both GM6001 and PMA treatment
decreased total levels of the 16 kDa SorV5 CTF (Figure 2a).
Anti-β-actin was used to demonstrate loading consistency
between wells.
The increase in 16 kDa sorV5 CTF resulting from γ-secre-
tase inhibition suggested that the SorV5 CTF was a precur-
sor to γ-secretase cleavage. We then expressed SorV5 in
cells lacking PS1 and PS2. Transfection of SorV5 into PS-/-
MEF cells resulted in an accumulation of the 16 kDa CTF
(Figure 2b). Cotransfection of PS-/- MEF with SorV5 and
either PS1 wt or a familial Alzheimer's disease linked
mutant PS1 (M139V) caused the 16 kDa SorV5 CTF band
to almost completely disappear (Figure 2b). Cotransfec-
tion of a dominant negative PS1 aspartate mutant
(D385E) did not reduce levels of the 16 kDa SorV5 CTF.
As expected, PS1 wt and M139V PS1 expression resulted
in generation of endoproteolyzed PS1 CTF (Figure 2b);
and expression of PS1 D385E resulted in accumulation of
the PS1 holo protein (Figure 2b).
Sortilin is processed into a CTF that is increased by γ-secretase inhibition or knockout Figure 2
Sortilin is processed into a CTF that is increased by γ-secretase inhibition or knockout. a) HEK 293T cells tran-
siently transfected with sorV5 produce a ~95 kDa holoprotein labeled by anti-V5 and anti-Sor NT antibody (not shown). A 
~16 kDa CTF of SorV5 is detected by an anti-V5 antibody is present in the cell lysate, and anti-SorNT detects a secreted frag-
ment of ~95 kDa (sSor) that does not label with anti-V5. The anti-V5 positive SorV5 CTF increased with γ-secretase inhibitor 
treatment (LY411,575 and compound E) and decreased with either PMA or a metalloprotease inhibitor, GM6001. sSor 
increased upon PMA treatment and decreased upon treatment with a metalloprotease inhibitor, GM6001. b) Mouse embry-
onic fibroblasts that are PS-/- were transiently transfected with SorV5 plus empty vector, PS1, PS1 M139V, or PS1 D385E. In the 
absence of PS1 or the presence of a dominant negative PS1 mutant (D385E) the levels 16 kDa SorV5 CTF are markedly 
increased. However, cotransfection of PS1 wt or PS1 familial Alzheimer's disease linked mutant (M139V) and SorV5 lead to an 
almost complete reduction in the levels of 16 kDa anti-V5 positive SorV5 CTF. Anti-β-actin was included as a loading control 
and anti-PS1ct antibody demonstrated that PS1 wt and M139V underwent endoproteolysis whereas D385E did not.
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γ-secretase processing of SorV5 CTF in lipid rafts
In figure 2b the 16 kDa CTF, a putative γ-secretase sub-
strate, increased when no PS was present. Under condi-
tions amenable to γ-secretase cleavage, the 16 kDa band
diminished but a smaller product band was not detected.
It has been demonstrated that γ-secretase activity is
enriched by sucrose gradient fractionation into choles-
terol rich microdomains called lipid rafts [64-67]. To fur-
ther confirm that the 16 kDa SorV5 CTF is a γ-secretase
substrate, cells stably overexpressing SorV5 were lysed in
2% CHAPSO to maintain the γ-secretase complex and
sucrose gradient fractionated as described in the Methods.
Fractions were analyzed by SDS PAGE and Western blot-
ting (Figure 3a). As previously shown, PS1 CTF and NH2-
terminal fragment (NTF) were enriched in the buoyant
fractions 4 and 5 whereas holo PS1 was primarily found
in more dense fractions 10, 11 and 12 (figure 3a). GS27,
a known lipid raft marker, was enriched in the buoyant
fractions as shown previously [64]. However, EEA1, an
early endosomal marker, was found primarily in dense
fractions. The 95 kDa holo SorV5 fractionated to both the
buoyant and dense fractions much like holo APP [64]. A
SorV5 CTF (~16 kDa) was enriched in the buoyant fac-
tions (Figure 3a, "4°C"). Incubation of the all fractions at
37°C for two hours generated a smaller SorV5 CTF (~13
kDa) that was only detected in buoyant fractions (Figure
3 "37°C"). These data provide evidence that the lipid raft
portion of the sucrose gradient contained all the compo-
nents necessary to generate a smaller SorV5 CTF upon
incubation at 37°C.
Having observed the in vitro generation of a smaller SorV5
CTF in fractions 4 and 5 as a result of incubating at 37°C
for 2 hours, we repeated the experiment with cells that
had been pretreated with 50 µM IL-aldehyde, a γ-secretase
inhibitor. These cells were lysed and sucrose gradient frac-
tionated. Buoyant fractions 4 and 5 were combined and
equal aliquots were incubated at 37°C for two hours plus
and minus γ-secretase inhibitors. During the same period
a negative control was incubated at 4°C for two hours. As
shown in Figure 3a, when the buoyant fractions were
incubated at 37°C for two hours a smaller SorV5 CTF
band was generated (figure 3b DMSO). In the sample that
remained at 4°C during the incubation period or those
incubated in the presence of γ-secretase inhibitors no
smaller SorV5 CTF was detected (Figure 3b). Furthermore,
generation of the smaller SorV5 CTF was inhibited by
another  γ-secretase inhibitor (LY411,575) in a dose
dependant fashion (Figure 3c). Anti-PS1NT antibody was
used to demonstrate loading consistency.
SorCS1b, evidence for α and γ-secretase processing of a 
second mammalian Vps10p
To further establish that the mammalian Vps10p contain-
ing family members are processed by α and γ-secretase
similar experiments were performed with SorCS1b tagged
with V5 at the COOH-terminus (SorCS1bV5). Consistent
with previous studies showing that the untagged SorCS1b
or His tagged holoprotein was a ~130 kDa [68], transfec-
tion of the SorCS1bV5 resulted in expression of a 130 kDa
protein that was detected by anti-V5 (figure 4a). Transfec-
tion of SorCS1bV5 into PS-/- MEF cells resulted in an
increase in the 13 kDa CTF (Figure 4a). Cotransfection of
PS-/- MEF with SorCS1bV5 and either PS1 wt or a familial
Alzheimer's disease linked mutant PS1 (M139V) caused a
decrease in the 13 kDa SorV5 CTF band (Figure 4a).
Cotransfection of a dominant negative PS1 aspartate
mutant (D385E) did not reduce levels of the 13 kDa
SorCS1bV5 CTF. Sucrose gradient fractionation of a cell
lysate from HEK cells stably overexpressing SorCS1bV5
lead to an enrichment of a ~13 kDa SorCS1bV5 CTF in
buoyant fractions at 4 and 5 (Figure 4b). Incubating the
fractions at 37°C for two hours generated a faintly detect-
able anti-V5 positive band at ~10 kDa. More consistent
than the detection of this band, was a decrease in the 13
kDa SorCS1bV5 CTF band observed after incubation at
37°C for two hours (Figure 4c and 4d). The decrease in
the ~13 kDa SorCS1bV5 band was inhibited by both
Compound E (Figure 4c) and LY411,575 in a concentra-
tion dependent fashion (Figure 4d). Detection of the sol-
uble SorSC1b NH2-terminus in the media was not
possible due to the lack of a reliable NH2-terminal anti-
SorCS1 antibody.
PS dependant SorLA processing
Using a wt SorLA construct and a COOH-terminal anti-
SorLA antibody (anti-SorLAct) we have obtained evidence
that that SorLA is a γ-secretase substrate as well. The SorLA
holoprotein was detected by the SorLA COOH-terminal
antibody at 250 kDa (Figure 5) consistent with previous
reports [69]. Transfection of SorLA into PS-/- MEF cells
resulted in accumulation of a 15 kDa SorLA CTF detected
by an anti-SorLAct antibody (Figure 5). However, cotrans-
fections with SorLA and either PS1 wt or an familial
Alzheimer's disease linked mutant PS1 (M139V) caused a
decrease in the 15 kDa SorLA CTF (Figure 5). Cotransfec-
tion of sorLA with a dominant negative PS1 aspartate
mutant (D385E) did not alter levels of the 15 kDa SorLA
CTF.
Discussion
To date, more than 25 γ-secretase substrates have been
identified (Figure 1a). γ-Secretase cleavage of certain sub-
strates mediates normal physiologic signaling. Given the
growing list of substrates, it has been postulated that γ-
secretase may function much like the proteosome of the
membrane assisting in the degradation of type I trans-
membrane proteins by liberating them from the mem-
brane [70]. This notion may be supported by the
promiscuity with which γ-secretase cleaves multiple sub-Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
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strates at a variety of different sites (Figure 1a). It is possi-
ble that overexpression of type I transmembrane proteins
may result in non-physiologic γ-secretase cleavage. How-
ever, to date, all γ-secretase substrates initially identified
using overexpression studies in eukaryotic cells have
proven to be authentic endogenous substrates. Indeed,
numerous  γ-secretase substrates like APP, Notch, and
CD44 have withstood the scrutiny of genetic, biochemi-
Sucrose gradient fractionation of SorV5 overexpressing cells demonstrates enrichment of the 16 kDa CTF in buoyant "lipid  raft" fractions and generation of a smaller SorV5 CTF Figure 3
Sucrose gradient fractionation of SorV5 overexpressing cells demonstrates enrichment of the 16 kDa CTF in 
buoyant "lipid raft" fractions and generation of a smaller SorV5 CTF. a) HEK cells stably overexpressing sorV5 were 
sucrose gradient fractionated and 1 ml fractions were collected from the top. Each fraction was analyzed by SDS PAGE on 12% 
XT Bis-Tris SDS PAGE (MES Buffer) and Western blotting. "4°C" were samples that were maintained at 4°C until SDS PAGE 
loading buffer was added. "37°C" indicates samples that were incubated at 37°C for 2 hours and then prepared as western 
samples. A smaller SorV5 CTF was detected in fractions 4 and 5 of the 37°C incubated sample. Anti-V5 antibody detected the 
SorV5 holo protein at 95 kDa, a CTF at 16 kDa and a smaller CTF in the "37°C" lanes 4 and 5. Anti-GS27 was used as a lipid 
raft marker (fractions 4–5), Anti-EEA1 is an early endosomal marker that was not found in lipid raft. PS1 CTF and NTF were 
enriched in raft fractions 4 and 5. b) HEK cells stably overexpressing sorV5 were pretreated with a γ-secretase inhibitor (IL-
aldehyde) for 30 hours and sucrose gradient fractions 4, 5 were combined and analyzed for generation of the smaller SorV5 
CTF. Samples were equally divided and incubated at 37°C (4°C for control) in the absence or presence of γ-secretase inhibi-
tors, LY411575, and Compound E. A smaller SorV5 CTF band was detected as a result of incubation at 37°C but was blocked 
by γ-secretase inhibitors. c) Samples were prepared as in b). Generation of the smaller SorV5 CTF was inhibited in a dose 
dependant fashion by a γ-secretase inhibitor, LY411,575. Anti-PS1NT demonstrates the loading consistency.
c
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PS dependent γ-secretase cleavage of SorCS1bV5 in lipid rafts Figure 4
PS dependent γ-secretase cleavage of SorCS1bV5 in lipid rafts. a) Mouse embryonic fibroblasts that are PS-/- were 
transiently transfected with SorCS1bV5 in the same fashion as figure 3a. Cells transiently transfected with sorCS1bV5 produce 
a ~130 kDa holoprotein labeled by anti-V5. In the absence of PS1 or the presence of a dominant negative PS1 mutant (D385E) 
the levels 13 kDa SorCS1bV5 CTF are markedly increased. However, cotransfection of PS1 wt or PS1 familial Alzheimer's dis-
ease linked mutant (M139V) and SorCS1bV5 lead to a reduction in the levels of 13 kDa anti-V5 positive SorCS1bV5 CTF. Anti-
β-actin was included as a loading control and anti-PS1ct antibody demonstrated that PS1 wt and M139V underwent endoprote-
olysis whereas D385E did not. b) HEK cells stably overexpressing sorCS1bV5 were sucrose gradient fractionated and 1 ml 
fractions were collected from the top. Each fraction was analyzed by SDS PAGE on 12% XT Bis-Tris SDS PAGE (MES Buffer) 
and Western blotting. "4°C" were samples that were maintained at 4°C until SDS PAGE loading buffer was added. "37°C" indi-
cates samples that were incubated at 37°C for 2 hours and then prepared as western samples. A faint SorCS1bV5 CTF was 
detected in fractions 4 and 5 of the 37°C incubated sample. Anti-V5 antibody detected the SorV5 holo protein at 130 kDa, a 
CTF at 13 kDa and a smaller CTF in the "37°C" lanes 4 and 5. Anti-GS27 was used as a lipid raft marker (fractions 4–5), Anti-
EEA1 is an early endosomal marker that was not found in lipid raft. PS1 CTF and NTF were enriched in raft fractions 4 and 5. 
c) HEK cells stably overexpressing sorCS1bV5 were pretreated with a γ-secretase inhibitor (IL-aldehyde) for 30 hours and 
sucrose gradient fractions 4, 5 were combined and analyzed for generation of the smaller SorCS1bV5 CTF. Samples were 
equally divided and incubated at 37°C (4°C for control) in the absence or presence of γ-secretase inhibitors, LY411575, and 
Compound E. A smaller SorV5 CTF band was not detected as a result of incubation at 37°C but the disappearance of the 13 
kDa SorCS1bV5 CTF was blocked by γ-secretase inhibitors. d) Samples were prepared as in b). Disappearance of the 
SorCS1bV5 CTF was inhibited in a dose dependant fashion by a γ-secretase inhibitor, LY411,575. Anti-PS1NT demonstrates 
the loading consistency.
a
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cal, animal model data that establish both their authentic-
ity as true γ-secretase substrates and the physiologic
relevance of γ-secretase cleavage.
Sortilin, SorCS1b and SorLA are all members of the mam-
malian Vps10p sorting receptor family. In this manuscript
we provide several lines of evidence that these proteins are
γ-secretase substrates. We detect truncated CTF derived
from COOH-terminally V5 epitope tagged Sortilin and
SorCS1b and untagged SorLA. These CTF appear to be
derived from the holoproteins by an α-secretase like activ-
ity. γ-Secretase inhibitors and expression of the proteins in
presenilin knockout cells results in marked accumulation
of these CTF, a phenomena reversed by expression wt or
FAD-linked mutant PS1. These CTF are enriched in buoy-
ant lipid raft fractions where γ-secretase activity resides.
Incubation of SorV5 or SorCS1bV5 CTF containing raft
fractions leads to generation of a smaller cleavage product
in the case of Sortilin and a decrease of the CTF in the case
of SorCS1bV5. The generation of the smaller SorV5 CTF
and the decrease in SorCS1bV5 CTF are inhibited by a γ-
secretase inhibitor. Collectively these data indicate that γ-
secretase has the capacity to cleave overexpressed Sortilin,
SorCS1b and SorLA.
During the preparation of this manuscript evidence was
reported that SorLA was a γ-secretase substrate [28]. Bohm
et al demonstrated that Myc tagged SorLA underwent PS
dependent  γ-secretase processing and that following γ-
secretase cleavage the cytoplasmic portion was found in
the nucleus [28]. Combined with our data, demonstrating
that Sortilin, SorCS1b, and SorLa are γ-secretase sub-
strates, these data provide evidence that the entire family
of mammalian Vps10p containing type I proteins may
contain important biologically active signaling peptides
in their COOH-termini.
Studies showing intramembrane γ-secretase cleavage of
endogenous Vps10p sorting receptor will be needed to
show that these proteins are in fact authentic γ-secretase
substrates. As noted before it is unlikely that the overex-
pression studies performed here will be misleading. Given
the complex trafficking, sorting, and signaling functions
mediated by mammalian Vps10p sorting receptors it will
be interesting to determine whether γ-secretase cleavage
regulates the normal function of these proteins. Indeed, it
may be that some of the trafficking deficits in PS deficient
cells could be attributed to the lack of γ-secretase cleavage
of several Vps10p proteins. Though speculative there is
some evidence that Vps10p receptors may play a role in
AD and in neuronal death. SorLA has been shown to be
down regulated in AD, and plays a role in APP trafficking
and Aβ production [56,71]. Neuronal death signaling was
shown to result from a complex of two γ-substrates, Sorti-
lin and p75NTR [13,14], in conjunction with proNGF or
proBDNF [47]. Additional studies are needed to clarify the
physiologic and possible pathologic role of γ-secretase
cleavage of mammalian Vps10p sorting receptors.
Materials and methods
DNA constructs
Full length Sortilin and SorCS1b plasmid constructs were
purchased from Origene. A V5 epitope was cloned into
the pCMV6-XL plasmid at the COOH-terminus immedi-
ately preceding the stop codon (SorV5 and SorCS1V5).
SorLA wt plasmid was described previously [57]. PS1 wt,
M139V, and D385E were described previously [34]. All
constructs were verified by sequencing.
DNA transfection of PS-/- MEF cells
Mouse embryonic fibroblasts (MEF) deficient in both PS1
and PS2 (PS-/-) were characterized previously [72]. Effi-
cient transfection of these cells was achieved using the
Amaxa nucleofector system. Briefly, using the Amaxa MEF
PS dependent cleavage of SorLA CTF Figure 5
PS dependent cleavage of SorLA CTF. Mouse embry-
onic fibroblasts that are PS-/- were transiently transfected 
with SorLA in the same fashion as figure 3a. Cells transiently 
transfected with SorLA produce a ~250 kDa holoprotein 
labeled by anti-V5. In the absence of PS1 or the presence of a 
dominant negative PS1 mutant (D385E) the levels 15 kDa 
anti-SorLAct positive SorLA CTF markedly increased. 
Cotransfection of PS1 wt or PS1 familial Alzheimer's disease 
linked mutant (M139V) and SorLA wt lead to a reduction in 
the levels of 15 kDa anti-SorLA positive SorLA CTF. Anti-β-
actin was included as a loading control and anti-PS1ct anti-
body demonstrated that PS1 wt and M139V underwent 
endoproteolysis whereas D385E did not.Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
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kit 2, 3 µg of DNA and 3 × 10^6 cells/reaction the trans-
fection was performed with the "O-05" mouse neuron
program. Transfected cells were plated on 10 cm plate
with 8 ml of growth media. Cells were harvested after 24
hours.
SorV5 and SorCS1bV5 stable cell lines and culture
Human embryonic kidney (HEK) 293 cells were trans-
fected in reduced serum Opti-Mem (Gibco) with 2 µg of
DNA and 8 µl of Fugene. Cells were incubated for 6 hours
and then allowed to equilibrate in standard growth media
(DMEM 2% fetal bovine serum, 8% normal calf serum,
1% penicillin streptomycin) for 24 hours. Selection anti-
biotic was then added to the cells and maintained
throughout the experiments. Transient expression experi-
ments were performed the same but with HEK 293T cells.
Cells treated with inhibitors were incubated for 18 hours
using the concentration reported and 1% DMSO. phorbol
12-myristate-13-acetate (PMA) treatment was performed
for 4 hours.
γ-secretase inhibitors
Inhibitors were all generated by the Mayo Clinic Chemis-
try core using published methods for each. All com-
pounds were verified by NMR and Mass Spectroscopy.
Lysis, antibodies, and Western blotting
Cells were lysed in 1% triton × 100 with 1× complete pro-
tease inhibitor (Roche) unless otherwise stated. Cell
lysates were then spun at 14,000 RPM for 2 minutes to
remove nuclei. BioRad XT loading buffer with reducing
solution was added to each sample. SDS-PAGE was per-
formed using BioRad Criterion gel system. 12% Bis-Tris
XT gels were used unless otherwise stated with BioRad
MES buffer. Gels were transferred to Millipore low-fluor
PVDF for 90 minutes and 160 volts. Membranes were
blocked in caesine (0.25%) and phosphate buffered
saline solution and primary antibodies were used at the
reported concentration in the blocking solution overnight
at 4°C. Anti-V5 (Invitrogen) and anti-β-actin antibody
(Sigma) antibodies were used at 1:1000. The anti-PS1 NTF
(A4 from Dr. Paul Fraser) antibody I think) and anti-PS1
CTF (490) were used at 1:1000. The anti-SorLAct antibody
was used at 1:500 [57]. Fluorescent antibodies containing
either the 680 or 800 fluorophore were incubated with the
membrane for 1 hour at room temperature at 1:20,000.
Fluorescently labeled protein detection was performed
using the Odyssey Scanner.
Gradient fractionation
Sucrose gradients were run as described previously [64].
Briefly, cells were washed with 5 mL of ice cold PBS (pH
7.4) and lysed in 2.5 mL of 2% CHAPSO 0.15 M Na Cit-
rate (pH 7.0) with 1× protease inhibitor cocktail (com-
plete PI, Roche). The cleared lysate was then sequentially
diluted with sucrose containing 0.15 M Na Citrate (pH
7.0) so that the final concentration of CHAPSO was
0.25% and sucrose was 45%. Four ml of this homogenate
was then applied to the bottom of the centrifuge tube, and
sequentially overlaid with 4 ml of 0.15 M Na Citrate (pH
7.0), 35% sucrose, 0.25% CHAPSO followed by 4 ml of
0.15 M Na Citrate (pH 7.0), 5% sucrose, 0.25% CHAPSO.
The gradient was centrifuged for 19 hrs at 39,000 rpm in
an SW-41 Ti rotor (Beckman) at 4°C. Following centrifu-
gation, 1 mL fractions were collected from the top of the
gradient.
Abbreviations
Abbreviations: CTF, COOH-terminal fragment; NTF,
NH2-terminal fragment; SorV5, sortilin that contain a
COOH-terminal V5 his epitope tag; SorCS1bV5, SorCs1b
that contain a COOH-terminal V5 his epitope tag; PS,
presenilin; APP, amyloid precursor protein; AD, Alzhe-
imer's disease; RIP, regulated intramembrane proteolysis;
NICD, Notch intracellular domain; CBP, CREBP binding
protein; DCC, deleted in colorectal cancer protein; PMA,
phorbol 12-myristate-13-acetate; anti-SorLA, antibody
specific to the COOH-terminus of SorLA; MEF, mouse
embryonic fibroblasts; proNGF, proform of nerve growth
factor; sSor, soluble NH2-terminal fragment of Sortilin;
HEK, human embryonic kidney cell line; PS-/-, MEF cells
that PS1 and PS2 are knocked out
Authors' contributions
ACN and TEG contributed to the conception, design,
analysis and interpretation of the data and were responsi-
ble to the manuscript preparation. ACN, TBL and CWZ
carried out the experiments in this manuscript. JJL pro-
vided critical reagents for these experiments. ACN, TEG,
and JJL all contributed to the interpretation and analysis
of data. All authors read and approved the final manu-
script.
Acknowledgements
We thank members of the Golde Lab for their critical analyses and thought-
ful contributions. This work was supported by the Mayo Foundation and an 
NIH/NINDS grant NS39072 to T.E.G.
References
1. Marlow L, Canet RM, Haugabook SJ, Hardy JA, Lahiri DK, Sambamurti
K:  APH1, PEN2, and Nicastrin increase Abeta levels and
gamma-secretase activity.  Biochem Biophys Res Commun 2003,
305:502-509.
2. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C:
Reconstitution of gamma-secretase activity.  Nat Cell Biol 2003,
5:486-488.
3. Wolfe MS, Xia WM, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe
DJ: Two transmembrane aspartates in presenilin-1 required
for presenilin endoproteolysis and gamma-secretase activ-
ity.  Nature 1999, 398:513-517.
4. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grze-
schik K-H, Multhaup G, Beyreuther K, Muller-Hill B: The precursor
of Alzheimer's disease amyloid A4 protein resembles a cell-
surface receptor.  Nature 1987, 325:733-736.Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
Page 10 of 11
(page number not for citation purposes)
5. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires
ligand-induced proteolytic release of intracellular domain
[see comments].  Nature 1998, 393:382-386.
6. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm
JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, et al.: A preseni-
lin-1-dependent gamma-secretase-like protease mediates
release of Notch intracellular domain.  Nature 1999,
398:518-522.
7. Struhl G, Greenwald I: Presenilin is required for activity and
nuclear access of Notch in Drosophila.  Nature 1999,
398:522-525.
8. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy
V, Baki L, Wen P, Efthimiopoulos S, Shao Z, et al.: A presenilin-1/
gamma-secretase cleavage releases the E-cadherin intracel-
lular domain and regulates disassembly of adherens junc-
tions.  Embo J 2002, 21:1948-1956.
9. Kim DY, MacKenzie Ingano LA, Kovacs DM: Nectin-1a, an immu-
noglobulin-like receptor involved in the formation of syn-
apses, is a substrate for presenilin/g-secretase-like cleavage.
J Biol Chem 2002, 9:9.
10. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK,
Edbauer D, Walter J, Steiner H, Haass C: Presenilin-dependent
Intramembrane Proteolysis of CD44 Leads to the Liberation
of Its Intracellular Domain and the Secretion of an Abeta –
like Peptide.  J Biol Chem 2002, 277:44754-44759.
11. Andersson CX, Fernandez-Rodriguez J, Laos S, Baeckstrom D, Haass
C, Hansson GC: Shedding and gamma-secretase-mediated
intramembrane proteolysis of the mucin-type molecule
CD43.  Biochem J 2005, 387:377-384.
12. Ni CY, Murphy MP, Golde TE, Carpenter G: gamma -Secretase
cleavage and nuclear localization of ErbB-4 receptor tyro-
sine kinase.  Science 2001, 294:2179-2181.
13. Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecter-
son LC: Proteolytic processing of the p75 neurotrophin
receptor and two homologs generates C-terminal fragments
with signaling capability.  J Neurosci 2003, 23:5425-5436.
14. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK,
Kim DS, Ryu SH, Chao MV, Kim TW: Regulated intramembrane
proteolysis of the p75 neurotrophin receptor modulates its
association with the TrkA receptor.  J Biol Chem 2003,
278:42161-42169.
15. May P, Reddy YK, Herz J: Proteolytic processing of low density
lipoprotein receptor-related protein mediates regulated
release of its intracellular domain.  J Biol Chem 2002,
277:18736-18743.
16. Hoe HS, Rebeck GW: Regulation of ApoE receptor proteolysis
by ligand binding.  Brain Res Mol Brain Res 2005, 137:31-39.
17. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De
Strooper B, David G: Syndecan 3 intramembrane proteolysis is
presenilin/gamma-secretase-dependent and modulates
cytosolic signaling.  J Biol Chem 2003, 278:48651-48657.
18. Taniguchi Y, Kim SH, Sisodia SS: Presenilin-dependent "gamma-
secretase" processing of deleted in colorectal cancer (DCC).
J Biol Chem 2003, 278:30425-30428.
19. Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L: Process-
ing of beta-amyloid precursor-like protein-1 and -2 by
gamma-secretase regulates transcription.  J Biol Chem 2002,
277:44195-44201.
20. Ikeuchi T, Sisodia SS: The Notch ligands, Delta1 and Jagged2,
are substrates for presenilin-dependent "gamma-secretase"
cleavage.  J Biol Chem 2003, 278:7751-7754.
21. LaVoie MJ, Selkoe DJ: The Notch ligands, Jagged and Delta, are
sequentially processed by alpha-secretase and presenilin/
gamma-secretase and release signaling fragments.  J Biol Chem
2003, 278:34427-34437.
22. Cowan JW, Wang X, Guan R, He K, Jiang J, Baumann G, Black RA,
Wolfe MS, Frank SJ: Growth hormone receptor is a target for
presenilin-dependent gamma-secretase cleavage.  J Biol Chem
2005, 280:19331-19342.
23. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H,
Kurosawa M, De Strooper B, Saftig P, Nukina N: beta Subunits of
voltage-gated sodium channels are novel substrates of beta-
site amyloid precursor protein-cleaving enzyme (BACE1)
and gamma-secretase.  J Biol Chem 2005, 280:23009-23017.
24. Gowrishankar K, Zeidler MG, Vincenz C: Release of a membrane-
bound death domain by gamma-secretase processing of the
p75NTR homolog NRADD.  J Cell Sci 2004, 117:4099-4111.
25. Araki Y, Miyagi N, Kato N, Yoshida T, Wada S, Nishimura M, Komano
H, Yamamoto T, De Strooper B, Yamamoto K, Suzuki T: Coordi-
nated metabolism of Alcadein and amyloid beta-protein pre-
cursor regulates FE65-dependent gene transactivation.  J Biol
Chem 2004, 279:24343-24354.
26. Cai J, Jiang WG, Grant MB, Boulton M: Pigment epithelium-
derived factor inhibits angiogenesis via regulated intracellu-
lar proteolysis of vascular endothelial growth factor recep-
tor 1.  J Biol Chem 2006, 281:3604-3613.
27. Biemesderfer D: Regulated intramembrane proteolysis of
megalin: Linking urinary protein and gene regulation in
proximal tubule?  Kidney Int 2006.
28. Bohm C, Seibel N, Henkel B, Steiner H, Haass C, Hampe W: SorLA
signaling by regulated intramembrane proteolysis.  J Biol Chem
2006.
29. Golde TE, Eckman CB: Physiologic and pathologic events medi-
ated by intramembranous and juxtamembranous proteoly-
sis.  Sci STKE 2003, 2003:RE4.
30. Yost CS, Hedgpeth J, Lingappa VR: A stop transfer sequence con-
fers predictable transmembrane orientation to a previously
secreted protein in cell-free systems.  Cell 1983, 34:759-766.
31. Xia W, Wolfe MS: Intramembrane proteolysis by presenilin
and presenilin-like proteases.  J Cell Sci 2003, 116:2839-2844.
32. Landman N, Kim TW: Got RIP? Presenilin-dependent intram-
embrane proteolysis in growth factor receptor signaling.
Cytokine Growth Factor Rev 2004, 15:337-351.
33. Pollack SJ, Lewis H: Secretase inhibitors for Alzheimer's dis-
ease: challenges of a promiscuous protease.  Curr Opin Investig
Drugs 2005, 6:35-47.
34. Murphy MP, Uljon SN, Golde TE, Wang R: FAD-linked mutations
in presenilin 1 alter the length of Abeta peptides derived
from betaAPP transmembrane domain mutants.  Biochim Bio-
phys Acta 2002, 1586:199-209.
35. Louvi A, Artavanis-Tsakonas S: Notch signalling in vertebrate
neural development.  Nat Rev Neurosci 2006, 7:93-102.
36. Fortini ME: Notch and presenilin: a proteolytic mechanism
emerges.  Curr Opin Cell Biol 2001, 13:627-634.
37. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo
T ,  D e  S t r o o p e r  B ,  Y u m o t o  E ,  S a y a  H :  Presenilin-dependent
gamma-secretase activity mediates the intramembranous
cleavage of CD44.  Oncogene 2003, 22:1511-1516.
38. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T,
Wong AJ, Saya H: Proteolytic release of CD44 intracellular
domain and its role in the CD44 signaling pathway.  J Cell Biol
2001, 155:755-762.
39. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R,
Robakis NK: A CBP binding transcriptional repressor pro-
duced by the PS1/epsilon-cleavage of N-cadherin is inhibited
by PS1 FAD mutations.  Cell 2003, 114:635-645.
40. Georgakopoulos A, Marambaud P, Efthimiopoulos S, Shioi J, Cui W,
Li HC, Schutte M, Gordon R, Holstein GR, Martinelli G, et al.: Prese-
nilin-1 forms complexes with the cadherin/catenin cell-cell
adhesion system and is recruited to intercellular and synap-
tic contacts.  Mol Cell 1999, 4:893-902.
41. Parent AT, Barnes NY, Taniguchi Y, Thinakaran G, Sisodia SS: Prese-
nilin attenuates receptor-mediated signaling and synaptic
function.  J Neurosci 2005, 25:1540-1549.
42. Hermey G, Sjogaard S, Petersen CM, Nykjaer A, Gliemann J:
Tumour necrosis factor-alpha convertase mediates ectodo-
main shedding of Vps10p-domain receptor family members.
Biochem J 2006.
43. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Ras-
mussen HH, Roigaard H, Gliemann J, Madsen P, Moestrup SK: Molec-
ular identification of a novel candidate sorting receptor
purified from human brain by receptor-associated protein
affinity chromatography.  J Biol Chem 1997, 272:3599-3605.
44. Mazella J: Sortilin/neurotensin receptor-3: a new tool to inves-
tigate neurotensin signaling and cellular trafficking?  Cell Signal
2001, 13:1-6.
45. Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I:
Identification and characterization of SorCS, a third mem-
ber of a novel receptor family.  Biochem Biophys Res Commun
1999, 266:347-351.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Neurodegeneration 2006, 1:3 http://www.molecularneurodegeneration.com/content/1/1/3
Page 11 of 11
(page number not for citation purposes)
46. Gutekunst CA, Torre ER, Sheng Z, Yi H, Coleman SH, Riedel IB, Bujo
H: Stigmoid bodies contain type I receptor proteins SorLA/
LR11 and sortilin: new perspectives on their function.  J Histo-
chem Cytochem 2003, 51:841-852.
47. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen
C, Kliemannel M, Schwarz E, Willnow TE, et al.: Sortilin is essential
for proNGF-induced neuronal cell death.  Nature 2004,
427:843-848.
48. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM:
Sortilin/neurotensin receptor-3 binds and mediates degrada-
tion of lipoprotein lipase.  J Biol Chem 1999, 274:8832-8836.
49. Morinville A, Martin S, Lavallee M, Vincent JP, Beaudet A, Mazella J:
Internalization and trafficking of neurotensin via NTS3
receptors in HT29 cells.  Int J Biochem Cell Biol 2004, 36:2153-2168.
50. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani
P, Torkin R, Chen ZY, Lee FS, et al.: ProBDNF induces neuronal
apoptosis via activation of a receptor complex of p75NTR
and sortilin.  J Neurosci 2005, 25:5455-5463.
51. Yamazaki H, Bujo H, Kusunoki J, Seimiya K, Kanaki T, Morisaki N, Sch-
neider WJ, Saito Y: Elements of neural adhesion molecules and
a yeast vacuolar protein sorting receptor are present in a
novel mammalian low density lipoprotein receptor family
member.  J Biol Chem 1996, 271:24761-24768.
52. Taira K, Bujo H, Hirayama S, Yamazaki H, Kanaki T, Takahashi K, Ishii
I, Miida T, Schneider WJ, Saito Y: LR11, a mosaic LDL receptor
family member, mediates the uptake of ApoE-rich lipopro-
teins in vitro.  Arterioscler Thromb Vasc Biol 2001, 21:1501-1506.
53. Zhu Y, Bujo H, Yamazaki H, Hirayama S, Kanaki T, Takahashi K, Shi-
basaki M, Schneider WJ, Saito Y: Enhanced expression of the LDL
receptor family member LR11 increases migration of
smooth muscle cells in vitro.  Circulation 2002, 105:1830-1836.
54. Zhu Y, Bujo H, Yamazaki H, Ohwaki K, Jiang M, Hirayama S, Kanaki
T, Shibasaki M, Takahashi K, Schneider WJ, Saito Y: LR11, an LDL
receptor gene family member, is a novel regulator of
smooth muscle cell migration.  Circ Res 2004, 94:752-758.
55. Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis
D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, et al.: Molec-
ular dissection of the interaction between amyloid precursor
protein and its neuronal trafficking receptor SorLA/LR11.
Biochemistry 2006, 45:2618-2628.
56. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke
J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al.: Neuronal
sorting protein-related receptor sorLA/LR11 regulates
processing of the amyloid precursor protein.  Proc Natl Acad Sci
USA 2005, 102:13461-13466.
57. Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah
JJ:  The lipoprotein receptor LR11 regulates amyloid beta
production and amyloid precursor protein traffic in endo-
somal compartments.  J Neurosci 2006, 26:1596-1603.
58. Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, Caput D, Fer-
rara P, Vita N, Gully D, Maffrand JP, Vincent JP: The 100-kDa neu-
rotensin receptor is gp95/sortilin, a non-G-protein-coupled
receptor.  J Biol Chem 1998, 273:26273-26276.
59. Buxbaum J, Oishi M, Chen H, Pinkas-Kramarski R, Jaffe E, Gandy S,
Greengard P: Cholinergic agonists and interleukin 1 regulate
processing and secretion of the Alzheimer ß/A4 precursor.
Proc Natl Acad Sci USA 1992, 89:10075-10078.
60. Caporaso GL, Gandy SE, Buxbaum JD, Ramabhadran TV: Protein
phosphorylation regulates secretion of Alzheimer ß/A4 amy-
loid precursor protein.  Proc Natl Acad Sci USA 1992,
89:3055-3059.
61. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzhe-
imer amyloid precursor derivatives stimulated by activation
of muscarinic acetylcholine receptors.  Science 1992,
258:304-307.
62. Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ,
Manning D, Ravi S, Williamson JR, Lee VM-Y: Muscarinic regula-
tion of Alzheimer's disease amyloid precursor protein (APP)
secretion and amyloid ß-protein (Aß) production in human
neuronal NT2N cells.  J Biol Chem 1995, 270:4916-4922.
63. Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F: Shed-
ding of the amyloid precursor protein-like protein APLP2 by
disintegrin-metalloproteinases.  Febs J 2005, 272:5808-5820.
64. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi
T, Younkin LH, Younkin SG, Golde TE: Cholesterol-Dependent
gamma-Secretase Activity in Buoyant Cholesterol- Rich
Membrane Microdomains.  Neurobiol Dis 2002, 9:11-23.
65. Wada S, Morishima-Kawashima M, Qi Y, Misono H, Shimada Y,
Ohno-Iwashita Y, Ihara Y: Gamma-secretase activity is present
in rafts but is not cholesterol-dependent.  Biochemistry 2003,
42:13977-13986.
66. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC,
Xu H, Thinakaran G: Association of gamma-secretase with lipid
rafts in post-Golgi and endosome membranes.  J Biol Chem
2004, 279:44945-44954.
67. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita
T, Iwatsubo T, Hamakubo T, Kodama T: Association of active
gamma-secretase complex with lipid rafts.  J Lipid Res 2005,
46:904-912.
68. Hermey G, Keat SJ, Madsen P, Jacobsen C, Petersen CM, Gliemann J:
Characterization of sorCS1, an alternatively spliced recep-
tor with completely different cytoplasmic domains that
mediate different trafficking in cells.  J Biol Chem 2003,
278:7390-7396.
69. Lintzel J, Franke I, Riedel IB, Schaller HC, Hampe W: Characteriza-
tion of the VPS10 domain of SorLA/LR11 as binding site for
the neuropeptide HA.  Biol Chem 2002, 383:1727-1733.
70. Kopan R, Ilagan MX: Gamma-secretase: proteasome of the
membrane?  Nat Rev Mol Cell Biol 2004, 5:499-504.
71. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ,
Schaller C, Bujo H, Levey AI, Lah JJ: Loss of apolipoprotein E
receptor LR11 in Alzheimer disease.  Arch Neurol 2004,
61:1200-1205.
72. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De
Strooper B: Total inactivation of gamma-secretase activity in
presenilin-deficient embryonic stem cells.  Nat Cell Biol 2000,
2:461-462.